Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.

Wachiraphansakul N, Vongchaiudomchoke T, Manosroi W, Ruengorn C, Noppakun K, Ngamvichchukorn T, Sood MM, Thavorn K, Hutton B, Nochaiwong S

Diabetes, obesity & metabolism28 May 2026

PMID42209204DOI10.1111/dom.70884PepBankPUB-42209204

Publisher page PubMedAsk about this study

Jump to 24 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study24

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without type 2 diabetes, subcutaneous liraglutide 1.8 mg/day significantly decreased lean mass from baseline.
In plain wordsIn adults with overweight or obesity, liraglutide 1.8 mg/day reduced lean mass from baseline.
Peptide
Liraglutide
Outcome
DecreaseLean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Studied dose
1.8 mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
3 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Report a problemFND-4220920419
02HumanSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without type 2 diabetes, subcutaneous semaglutide 1.0 mg weekly significantly decreased lean mass from baseline.
In plain wordsIn adults with overweight or obesity, semaglutide 1.0 mg weekly reduced lean mass from baseline.
Peptide
Semaglutide
Outcome
DecreaseLean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Studied dose
1.0 mg-weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
3 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Report a problemFND-4220920420
03HumanSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without type 2 diabetes, subcutaneous tirzepatide 15 mg weekly significantly decreased lean mass from baseline.
In plain wordsIn adults with overweight or obesity, tirzepatide 15 mg weekly reduced lean mass from baseline.
Peptide
Tirzepatide
Outcome
DecreaseLean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Studied dose
15 mg-weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
3 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Report a problemFND-4220920421

Studies that did not test the peptide alone21

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased total body fat from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered total body fat more than control.
Peptide
Liraglutide
Outcome
DecreaseTotal body fat
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4220920401
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased total body fat from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered total body fat more than control.
Peptide
Semaglutide
Outcome
DecreaseTotal body fat
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4220920402
06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased total body fat from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered total body fat more than control.
Peptide
Tirzepatide
Outcome
DecreaseTotal body fat
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4220920403
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased fat mass from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered fat mass more than control.
Peptide
Liraglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4220920404
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased fat mass from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered fat mass more than control.
Peptide
Semaglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4220920405
09HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased fat mass from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered fat mass more than control.
Peptide
Tirzepatide
Outcome
DecreaseFat mass
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4220920406
10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased visceral adipose tissue area from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered visceral fat area more than control.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue area
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4220920407
11HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased visceral adipose tissue area from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered visceral fat area more than control.
Peptide
Semaglutide
Outcome
DecreaseVisceral adipose tissue area
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4220920408
12HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased visceral adipose tissue area from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered visceral fat area more than control.
Peptide
Tirzepatide
Outcome
DecreaseVisceral adipose tissue area
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4220920409
13HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased subcutaneous adipose tissue area from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered subcutaneous fat area more than control.
Peptide
Liraglutide
Outcome
DecreaseSubcutaneous adipose tissue area
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4220920410
14HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased subcutaneous adipose tissue area from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered subcutaneous fat area more than control.
Peptide
Semaglutide
Outcome
DecreaseSubcutaneous adipose tissue area
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4220920411
15HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased subcutaneous adipose tissue area from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered subcutaneous fat area more than control.
Peptide
Tirzepatide
Outcome
DecreaseSubcutaneous adipose tissue area
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4220920412
16HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased liver fat from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered liver fat more than control.
Peptide
Liraglutide
Outcome
DecreaseLiver fat
Study
n: not reported in source
Comparator
Control group
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4220920413
17HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased liver fat from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered liver fat more than control.
Peptide
Semaglutide
Outcome
DecreaseLiver fat
Study
n: not reported in source
Comparator
Control group
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4220920414
18HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found pooled subcutaneous GLP-1 drugs decreased liver fat from baseline more than control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs lowered liver fat more than control.
Peptide
Tirzepatide
Outcome
DecreaseLiver fat
Study
n: not reported in source
Comparator
Control group
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Regarding variations in treatment benefits on body composition, GLP-1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4220920415
19HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found no significant total lean-tissue change difference with pooled subcutaneous GLP-1 drugs versus control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs showed no significant total lean-tissue change difference versus control.
Peptide
Liraglutide
Outcome
No significant changeTotal lean tissue
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Musculoskeletal
Source sentences
Summary
No significant differences for change in total lean tissue were observed.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4220920416
20HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found no significant total lean-tissue change difference with pooled subcutaneous GLP-1 drugs versus control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs showed no significant total lean-tissue change difference versus control.
Peptide
Semaglutide
Outcome
No significant changeTotal lean tissue
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Musculoskeletal
Source sentences
Summary
No significant differences for change in total lean tissue were observed.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4220920417
21HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, with or without T2D, the network meta-analysis found no significant total lean-tissue change difference with pooled subcutaneous GLP-1 drugs versus control.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 drugs showed no significant total lean-tissue change difference versus control.
Peptide
Tirzepatide
Outcome
No significant changeTotal lean tissue
Study
n: not reported in source
Comparator
Control group
Outcome group
Body composition · Musculoskeletal
Source sentences
Summary
No significant differences for change in total lean tissue were observed.
4 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
Summary · context
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4220920418
22HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a network meta-analysis of adults with overweight or obesity, with or without type 2 diabetes, the listed liraglutide, semaglutide and tirzepatide doses significantly decreased lean mass from baseline, with SMDs ranging from -1.09 to -0.50.
In plain wordsIn adults with overweight or obesity in a review, the listed liraglutide, semaglutide and tirzepatide doses reduced lean mass.
Peptide
Liraglutide
Outcome
DecreaseLean-mass SMD range for the listed doses
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Measurements
SMD range
−1.09 to −0.5
liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly
Source sentences
Summary
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
3 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4220920422
23HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In a network meta-analysis of adults with overweight or obesity, with or without type 2 diabetes, the listed liraglutide, semaglutide and tirzepatide doses significantly decreased lean mass from baseline, with SMDs ranging from -1.09 to -0.50.
In plain wordsIn adults with overweight or obesity in a review, the listed liraglutide, semaglutide and tirzepatide doses reduced lean mass.
Peptide
Semaglutide
Outcome
DecreaseLean-mass SMD range for the listed doses
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Measurements
SMD range
−1.09 to −0.5
liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly
Source sentences
Summary
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
3 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4220920423
24HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In a network meta-analysis of adults with overweight or obesity, with or without type 2 diabetes, the listed liraglutide, semaglutide and tirzepatide doses significantly decreased lean mass from baseline, with SMDs ranging from -1.09 to -0.50.
In plain wordsIn adults with overweight or obesity in a review, the listed liraglutide, semaglutide and tirzepatide doses reduced lean mass.
Peptide
Tirzepatide
Outcome
DecreaseLean-mass SMD range for the listed doses
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Measurements
SMD range
−1.09 to −0.5
liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly
Source sentences
Summary
However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly (SMDs ranged from -1.09 to -0.50) significantly decreased lean mass from baseline.
3 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP-1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D…
Summary · context
A frequentist network meta-analysis was employed using a random-effects model and reported as standardised mean differences (SMDs).
Summary · context
We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4220920424

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.